On June 4, 2025, Cue Biopharma appointed Jill Broadfoot as a new board member and chair of the Audit Committee, approved a new 2025 Stock Incentive Plan, and reported the resignation of CFO Kerri-Ann Millar effective June 13, 2025. Additionally, stockholders voted to increase authorized shares from 210 million to 310 million and approved the 2025 Plan with significant support.